Using low-dose Decitabine with COP chemotherapy for relapsed DLBCL

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the combination of low-dose Decitabine and the COP chemotherapy regimen in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL). Decitabine acts as a DNA methyltransferase inhibitor, aiming to reverse DNA methylation and promote tumor cell differentiation or apoptosis. The study focuses on patients who have not responded to standard treatments and evaluates the effectiveness of this novel combination therapy. Participants will receive the D-COP regimen, which includes Decitabine alongside traditional chemotherapy agents.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histopathology confirmed as DLBCL.
2. Relapsed and refractory patients.
3. Age ≥ 18 years old.
4. ECOG ≥ 3.
5. Women are not lactating, not pregnant, and agree not to become pregnant during the study period and within the next 12 months. Male patients agree that their spouse is not pregnant during the study period and within the next 12 months。
6. There is an assessable lesion (lymph node diameter ≥ 1.0cm; or a dermatologic lesion that can be assessed by a physical examination)Signed informed consent

Exclusion Criteria:

1. Bone marrow involvement and lymphoma cells ≥ 25%.
2. Severe abnormal liver and kidney function (alanine aminotransferase, bilirubin, creatinine\> 3 times the upper limit of normal).
3. Uncontrolled active infections.
4. Organic heart disease and clinical symptoms or abnormal heart function (NYHA ≥ 2).
5. Simultaneous presence of other tumors.
6. Other psychological conditions that prevent patients from participating in the study or signing informed consent

Where it's running

• The First Affiliated Hospital of Harbin Medical University, Department of Hematology, Lymphoma Ward
  Harbin, Heilongjiang, China Recruiting

Study contacts

• Study coordinator: Qi Zhou, Master
• Email: kykbgs123@163.com
• Phone: 0451-85552320

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma

  This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.

  Recruiting Phase 1 Leukos Biotech S.L. · Barcelona, Barcelona · NCT07914348

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma

  This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07779018

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Glofit-GemOx Bridging to Liso-cel for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests whether a bridging therapy with Glofit-GemOx followed by lisocabtagene maraleucel helps people with relapsed or refractory large B-cell lymphoma.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07711483

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.